F10 and interstitial lung disease: Among patients who were diagnosed with ILD during the follow-up period, antifibrotic agents (pirfenidone or nintedanib) were received by 9.18 per 100 patients in the FXa inhibitor group, 5.56 per 100 patients in the dabigatran group, and 3.03 per 100 patients in the warfarin group.